140 related articles for article (PubMed ID: 35293326)
1. Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.
Nash P
J Rheumatol; 2022 Jun; 49(6 Suppl 1):44-47. PubMed ID: 35293326
[TBL] [Abstract][Full Text] [Related]
2. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.
Kerschbaumer A; Smolen JS; Nash P; Doerner T; Dougados M; Fleischmann R; Geissler K; McInnes IB; Takeuchi T; Trauner M; Winthrop K; de Wit M; Boehncke WH; Falzon L; van der Heijde D
RMD Open; 2020 Nov; 6(3):. PubMed ID: 33188136
[TBL] [Abstract][Full Text] [Related]
3. [Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].
Fiehn C
Dtsch Med Wochenschr; 2024 Mar; 149(6):326-330. PubMed ID: 38412990
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD; Stovin C; Alveyn E; Adeyemi O; Chan CKD; Patel V; Adas MA; Atzeni F; Ng KKH; Rutherford AI; Norton S; Cope AP; Galloway JB
Ann Rheum Dis; 2023 Aug; 82(8):1059-1067. PubMed ID: 37247942
[TBL] [Abstract][Full Text] [Related]
5. Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.
Yang V; Kragstrup TW; McMaster C; Reid P; Singh N; Haysen SR; Robinson PC; Liew DFL
Drug Saf; 2023 Nov; 46(11):1049-1071. PubMed ID: 37490213
[TBL] [Abstract][Full Text] [Related]
6. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
7. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Bechman K; Yates M; Galloway JB
Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
[TBL] [Abstract][Full Text] [Related]
8. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
Alduraibi FK; Singh JA
Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
[TBL] [Abstract][Full Text] [Related]
9. Start RA treatment - Biologics or JAK-inhibitors?
Caporali R; Germinario S; Kacsándi D; Choy E; Szekanecz Z
Autoimmun Rev; 2024 Jan; 23(1):103429. PubMed ID: 37634678
[TBL] [Abstract][Full Text] [Related]
10. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study.
Martinez-Molina C; Gich I; Diaz-Torné C; Park HS; Feliu A; Vidal S; Corominas H
Sci Rep; 2024 Jan; 14(1):172. PubMed ID: 38168532
[TBL] [Abstract][Full Text] [Related]
11. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
[TBL] [Abstract][Full Text] [Related]
12. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
Szekanecz Z; Buch MH; Charles-Schoeman C; Galloway J; Karpouzas GA; Kristensen LE; Ytterberg SR; Hamar A; Fleischmann R
Nat Rev Rheumatol; 2024 Feb; 20(2):101-115. PubMed ID: 38216757
[TBL] [Abstract][Full Text] [Related]
14. Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort.
Gentileschi S; Gaggiano C; Damiani A; Coccia C; Bernardini P; Cazzato M; D'Alessandro F; Vallifuoco G; Terribili R; Bardelli M; Baldi C; Cantarini L; Mosca M; Frediani B; Guiducci S
Clin Exp Med; 2024 Mar; 24(1):62. PubMed ID: 38554250
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitor-Tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data.
Wang L; Zhao B
Expert Opin Drug Saf; 2023; 22(12):1317-1320. PubMed ID: 37722813
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Tokareva K; Reid P; Yang V; Liew D; Peterson AC; Baraff A; Giles J; Singh N
Expert Rev Clin Immunol; 2023; 19(11):1385-1397. PubMed ID: 37596779
[TBL] [Abstract][Full Text] [Related]
17. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis.
Corrao S
Intern Emerg Med; 2023 Nov; 18(8):2157-2161. PubMed ID: 37898967
[TBL] [Abstract][Full Text] [Related]
18. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
[TBL] [Abstract][Full Text] [Related]
19. In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y.
Schattner A
Ann Intern Med; 2023 Jul; 176(7):JC83. PubMed ID: 37399557
[TBL] [Abstract][Full Text] [Related]
20. Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study.
de Souza S; Williams R; Nikiphorou E
BMC Rheumatol; 2024 Jan; 8(1):1. PubMed ID: 38229170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
